AI Drug Discovery: Top Investors and Top Companies

Deep Knowledge Ventures (DKV) is a Hong Kong based investment fund with teams in London, Geneva, and San Francisco. The fund primarily invests in DeepTech, AI, and advanced biomedicine. In 2015, DKV incorporated a subsidiary investment fund Deep Knowledge Life Sciences (DKLS), a London-based venture fund, focused on disruptive biopharmaceutical, medical device, and healthcare companies in a partnership with scientists at the universities of Oxford and Cambridge. DKLS it has been the lead investor so far in a number of promising biomedicine and longevity companies: Insilico Medicine (and the consortium of companies around Insilico Medicine, including Youth Laboratories and Longenesis) and other companies in the fields of Geroscience, NeuroTech, Preventive Medicine, AgeTech and Longevity. The Pharma Division of Deep Knowledge Analytics is the leading analytical entity of DKLS specifically focused on deep intelligence of the pharma industry and the AI for Drug Discovery sector. So far its reports have been covered by top-tier tech, business and finance media -- including Forbes, Financial Times, acknowledged by many other authoritative entities such as MIT Review -- and have been recognized by industry experts and executives as the dominant source of sophisticated industry analysis, pragmatic forecasting and tangible benchmarking on the AI in Pharma sector.